Adam Mor
Overview
Explore the profile of Adam Mor including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
100
Citations
1889
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Moore E, Strazza M, Hu X, Tymm C, Paiola M, Shannon M, et al.
bioRxiv
. 2024 Dec;
PMID: 39677716
One Sentence Summary: Adaptor protein PAG links to the actin cytoskeleton, and this link is essential for T cell synapse formation and cytotoxic function.
2.
Zhong J, Lerrer S, Mor A
Bio Protoc
. 2024 Sep;
14(17):e5057.
PMID: 39282229
PD-1 is an immune checkpoint on T cells. Antibodies to PD-1 or its ligand PD-L1 are gaining popularity as a leading immunotherapy approach. In the US, 40% of all cancer...
3.
Hao L, Lerrer S, Paiola M, Moore E, Gartshteyn Y, Song R, et al.
Mol Ther Oncol
. 2024 Jul;
32(3):200839.
PMID: 39072290
Targeting immune checkpoint receptors on T cells is a common cancer treatment strategy. Frequently, this is accomplished through antibodies targeting the ligand of inhibitory co-receptors. Blocking the immune checkpoint PD-1...
4.
Strazza M, Song R, Hiner S, Mor A
Immunology
. 2024 Jul;
173(2):248-257.
PMID: 38952142
Targeting immune receptors on T cells is a common strategy to treat cancer and autoimmunity. Frequently, this is accomplished through monoclonal antibodies targeting the ligand binding sites of stimulatory or...
5.
Gartshteyn Y, Geraldino-Pardilla L, Khalili L, Bukhari S, Lerrer S, Winchester R, et al.
Front Immunol
. 2024 Mar;
15:1327437.
PMID: 38550577
Introduction: T follicular (TFH) and peripheral helper (TPH) cells have been increasingly recognized as a pathogenic subset of CD4 T cells in systemic lupus erythematosus (SLE). The SLAM Associated Protein...
6.
Hu X, Bukhari S, Tymm C, Adam K, Lerrer S, Henick B, et al.
J Immunother Cancer
. 2024 Mar;
12(3).
PMID: 38519059
Background: Immune checkpoint inhibitors (ICIs) have improved outcomes and extended patient survival in several tumor types. However, ICIs often induce immune-related adverse events (irAEs) that warrant therapy cessation, thereby limiting...
7.
Philips E, Liu J, Kvalvaag A, Morch A, Tocheva A, Ng C, et al.
Sci Immunol
. 2024 Mar;
9(93):eade6256.
PMID: 38457513
Programmed cell death-1 (PD-1) is a potent immune checkpoint receptor on T lymphocytes. Upon engagement by its ligands, PD-L1 or PD-L2, PD-1 inhibits T cell activation and can promote immune...
8.
Straube J, Bukhari S, Lerrer S, Winchester R, Gartshteyn Y, Henick B, et al.
Arthritis Res Ther
. 2024 Jan;
26(1):32.
PMID: 38254179
Background: PD-1 is an immune checkpoint on T cells, and interventions to block this receptor result in T cell activation and enhanced immune response to tumors and pathogens. Reciprocally, despite...
9.
Straube J, Bukhari S, Lerrer S, Winchester R, Henick B, Dragovich M, et al.
bioRxiv
. 2023 Nov;
PMID: 38014321
Background: PD-1 is an immune checkpoint on T cells and interventions to block this receptor result in T cell activation and enhanced immune response to tumors. Paired to that, and...
10.
Hao L, Lerrer S, Song R, Goeckeritz M, Hu X, Mor A
bioRxiv
. 2023 Nov;
PMID: 38014028
Targeting immune checkpoint receptors on T cells is a common cancer treatment strategy. Frequently, this is accomplished through antibodies targeting the ligand of inhibitory co-receptors. Blocking the immune checkpoint PD-1...